Index RUT
P/E -
EPS (ttm) -5.37
Insider Own 3.33%
Shs Outstand 117.66M
Perf Week -3.78%
Market Cap 6.33B
Forward P/E -
EPS next Y -4.86
Insider Trans -6.57%
Shs Float 113.74M
Perf Month -4.97%
Income -545.28M
PEG -
EPS next Q -1.24
Inst Own 113.90%
Short Float 16.01%
Perf Quarter 0.47%
Sales 3.13M
P/S 2021.27
EPS this Y 6.02%
Inst Trans -1.19%
Short Ratio 12.76
Perf Half Y -18.57%
Book/sh 0.92
P/B 58.22
EPS next Y 5.10%
ROA -47.34%
Short Interest 18.21M
Perf Year 68.19%
Cash/sh 8.98
P/C 5.98
EPS next 5Y 15.00%
ROE -
52W Range 25.98 - 110.25
Perf YTD -35.60%
Dividend Est. -
P/FCF -
EPS past 5Y -22.79%
ROI -62.77%
52W High -51.23%
Beta 0.78
Dividend TTM -
Quick Ratio 10.39
Sales past 5Y 12.30%
Gross Margin -312.44%
52W Low 106.97%
ATR (14) 2.41
Dividend Ex-Date -
Current Ratio 10.39
EPS Y/Y TTM 5.62%
Oper. Margin -16148.37%
RSI (14) 42.82
Volatility 5.56% 4.20%
Employees 423
Debt/Eq 7.28
Sales Y/Y TTM -68.51%
Profit Margin -17398.82%
Recom 1.56
Target Price 79.75
Option/Short Yes / Yes
LT Debt/Eq 7.00
EPS Q/Q 2.34%
Payout -
Rel Volume 2.23
Prev Close 55.60
Sales Surprise -96.73%
EPS Surprise -23.98%
Sales Q/Q -71.28%
Earnings Aug 08 AMC
Avg Volume 1.43M
Price 53.77
SMA20 -3.47%
SMA50 -4.40%
SMA200 -14.40%
Trades
Volume 3,186,355
Change -3.29%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-24 Downgrade
Goldman
Buy → Neutral
$85 → $60
Jan-24-24 Downgrade
UBS
Buy → Neutral
$61 → $92
Jan-05-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$60 → $90
Nov-09-23 Initiated
Goldman
Buy
$50
Nov-07-23 Initiated
B. Riley Securities
Buy
$66
Aug-15-23 Initiated
SVB Securities
Outperform
$58
Feb-17-23 Initiated
BofA Securities
Neutral
$49
Dec-23-22 Reiterated
Needham
Buy
$60 → $58
Dec-20-22 Initiated
Truist
Buy
$60
Oct-11-22 Initiated
UBS
Buy
$80
Jan-28-22 Initiated
Goldman
Buy
$74
Dec-22-21 Initiated
Oppenheimer
Outperform
$55
Dec-10-21 Initiated
JP Morgan
Overweight
$58
Oct-07-21 Initiated
Jefferies
Buy
$75
Mar-12-21 Initiated
Wolfe Research
Outperform
$50
Feb-18-21 Initiated
Barclays
Overweight
$28
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$22 → $41
Oct-29-20 Initiated
Goldman
Neutral
$16
Jul-10-20 Initiated
Raymond James
Strong Buy
$39
May-05-20 Initiated
Mizuho
Buy
$31
Show Previous Ratings
Sep-19-24 04:08PM
(Investor's Business Daily)
04:00PM
09:22AM
(Investor's Business Daily)
Sep-09-24 01:11PM
07:30AM
01:55AM
Loading…
Sep-08-24 01:55AM
Sep-05-24 04:00PM
Sep-04-24 04:00PM
01:16AM
Sep-01-24 04:27AM
03:51AM
Aug-29-24 04:00PM
Aug-22-24 07:01PM
Aug-09-24 10:20AM
Aug-08-24 09:59PM
05:10PM
Loading…
05:10PM
04:13PM
(Associated Press Finance)
04:00PM
01:01AM
Aug-01-24 04:00PM
Jul-30-24 07:30AM
Jul-25-24 04:00PM
10:01AM
Jul-23-24 07:01PM
Jul-17-24 08:00AM
Jul-16-24 07:30AM
Jul-11-24 08:00AM
(Investor's Business Daily)
08:00AM
(Investor's Business Daily)
Jul-10-24 01:42AM
Jul-03-24 04:00PM
02:46AM
Loading…
Jul-02-24 02:46AM
Jun-26-24 02:11PM
Jun-18-24 01:49AM
Jun-17-24 07:30AM
Jun-12-24 02:37AM
Jun-10-24 07:00PM
Jun-05-24 07:55AM
06:14AM
03:00AM
Jun-04-24 04:00PM
02:38AM
May-29-24 04:00PM
May-28-24 04:00PM
May-27-24 06:28PM
06:13PM
May-24-24 11:12AM
May-23-24 09:40AM
(FierceBiotech.com) -17.31%
07:50AM
May-22-24 11:30PM
04:10PM
04:02PM
04:00PM
May-17-24 07:30AM
May-15-24 07:30AM
May-14-24 04:01PM
(Investor's Business Daily)
May-13-24 05:24PM
(The Wall Street Journal) -6.78%
04:08PM
(Investor's Business Daily)
09:43AM
(Investor's Business Daily)
09:33AM
09:33AM
09:11AM
May-10-24 12:37PM
May-09-24 10:48AM
10:46AM
07:01AM
May-08-24 09:00PM
05:18PM
05:10PM
04:06PM
(Associated Press Finance)
04:00PM
07:30AM
07:30AM
02:23AM
May-07-24 05:02PM
04:00PM
02:04PM
May-02-24 04:00PM
May-01-24 10:01AM
Apr-29-24 04:00PM
Apr-26-24 04:44PM
06:00AM
Apr-24-24 04:00PM
Apr-10-24 09:27AM
07:30AM
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-13-24 02:25PM
Mar-12-24 06:46AM
(Thomson Reuters StreetEvents)
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
(FierceBiotech.com) -9.75%
10:22AM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Malik Fady Ibraham EVP Research & Development Sep 17 '24 Option Exercise 7.96 5,300 42,188 128,220 Sep 17 04:15 PM Malik Fady Ibraham EVP Research & Development Sep 17 '24 Sale 56.77 7,300 414,401 120,920 Sep 17 04:15 PM Blum Robert I President & CEO Sep 16 '24 Option Exercise 6.67 5,000 33,350 402,456 Sep 17 04:10 PM Blum Robert I President & CEO Sep 16 '24 Sale 55.99 5,000 279,950 397,456 Sep 17 04:10 PM FADY MALIK Officer Sep 17 '24 Proposed Sale 56.77 7,300 414,401 Sep 17 04:03 PM ROBERT BLUM Officer Sep 16 '24 Proposed Sale 55.99 5,000 279,962 Sep 16 04:29 PM B LYNNE PARSHALL Director Sep 09 '24 Proposed Sale 54.92 5,000 274,582 Sep 09 04:12 PM PARSHALL B LYNNE Director Sep 09 '24 Option Exercise 21.61 5,000 108,050 25,600 Sep 09 04:05 PM PARSHALL B LYNNE Director Sep 09 '24 Sale 54.92 5,000 274,600 20,600 Sep 09 04:05 PM Malik Fady Ibraham EVP Research & Development Sep 03 '24 Option Exercise 7.96 5,300 42,188 128,220 Sep 03 05:14 PM Malik Fady Ibraham EVP Research & Development Sep 03 '24 Sale 57.01 7,384 420,973 122,920 Sep 03 05:14 PM Blum Robert I President & CEO Sep 03 '24 Option Exercise 6.67 5,000 33,350 402,456 Sep 03 05:09 PM Blum Robert I President & CEO Sep 03 '24 Sale 57.03 5,000 285,150 397,456 Sep 03 05:09 PM ROBERT BLUM Officer Sep 03 '24 Proposed Sale 57.03 5,000 285,126 Sep 03 04:08 PM FADY MALIK Officer Sep 03 '24 Proposed Sale 57.01 7,384 420,973 Sep 03 04:07 PM B LYNNE PARSHALL Director Aug 26 '24 Proposed Sale 57.26 5,000 286,288 Aug 26 04:14 PM PARSHALL B LYNNE Director Aug 26 '24 Option Exercise 21.61 5,000 108,050 25,600 Aug 26 04:00 PM PARSHALL B LYNNE Director Aug 26 '24 Sale 57.26 5,000 286,300 20,600 Aug 26 04:00 PM Malik Fady Ibraham EVP Research & Development Aug 20 '24 Option Exercise 7.96 5,300 42,188 130,304 Aug 22 04:00 PM Malik Fady Ibraham EVP Research & Development Aug 20 '24 Sale 56.25 7,300 410,638 125,004 Aug 22 04:00 PM FADY MALIK Officer Aug 20 '24 Proposed Sale 56.26 7,300 410,669 Aug 20 04:08 PM Blum Robert I President & CEO Aug 12 '24 Option Exercise 6.67 11,500 76,705 410,912 Aug 12 05:32 PM Blum Robert I President & CEO Aug 12 '24 Sale 55.17 11,500 634,455 399,412 Aug 12 05:32 PM PARSHALL B LYNNE Director Aug 12 '24 Option Exercise 21.61 5,000 108,050 25,600 Aug 12 05:31 PM PARSHALL B LYNNE Director Aug 12 '24 Sale 55.20 5,000 276,000 20,600 Aug 12 05:31 PM B LYNNE PARSHALL Director Aug 12 '24 Proposed Sale 55.20 5,000 276,007 Aug 12 04:24 PM ROBERT BLUM Officer Aug 12 '24 Proposed Sale 55.17 11,500 634,470 Aug 12 04:21 PM Malik Fady Ibraham EVP Research & Development Aug 07 '24 Option Exercise 7.96 5,300 42,188 127,004 Aug 07 08:06 PM Malik Fady Ibraham EVP Research & Development Aug 06 '24 Sale 53.71 7,300 392,090 121,704 Aug 07 08:06 PM FADY MALIK Officer Aug 06 '24 Proposed Sale 53.71 7,300 392,096 Aug 06 04:14 PM PARSHALL B LYNNE Director Jul 29 '24 Option Exercise 21.61 5,000 108,050 25,600 Jul 31 04:39 PM PARSHALL B LYNNE Director Jul 29 '24 Sale 59.84 5,000 299,200 20,600 Jul 31 04:39 PM Blum Robert I President & CEO Jul 30 '24 Option Exercise 6.67 11,500 76,705 410,912 Jul 31 04:36 PM Blum Robert I President & CEO Jul 30 '24 Sale 59.49 11,500 684,135 399,412 Jul 31 04:36 PM ROBERT BLUM Officer Jul 30 '24 Proposed Sale 59.49 11,500 684,158 Jul 30 04:13 PM B LYNNE PARSHALL Director Jul 29 '24 Proposed Sale 59.84 5,000 299,217 Jul 29 04:17 PM Malik Fady Ibraham EVP Research & Development Jul 23 '24 Option Exercise 7.96 5,300 42,188 134,304 Jul 23 04:47 PM Malik Fady Ibraham EVP Research & Development Jul 23 '24 Sale 57.02 7,300 416,246 129,004 Jul 23 04:47 PM PARSHALL B LYNNE Director Jul 15 '24 Option Exercise 10.68 5,000 53,400 25,600 Jul 16 05:05 PM PARSHALL B LYNNE Director Jul 15 '24 Sale 55.82 5,000 279,100 20,600 Jul 16 05:05 PM Blum Robert I President & CEO Jul 10 '24 Option Exercise 6.67 5,767 38,466 410,912 Jul 10 05:24 PM Blum Robert I President & CEO Jul 10 '24 Sale 54.29 11,500 624,335 399,412 Jul 10 05:24 PM Malik Fady Ibraham EVP Research & Development Jul 09 '24 Option Exercise 7.96 5,300 42,188 138,304 Jul 09 06:15 PM Malik Fady Ibraham EVP Research & Development Jul 09 '24 Sale 55.90 7,300 408,103 131,004 Jul 09 06:15 PM Harrington Robert Arthur Director Jul 05 '24 Sale 54.61 253 13,816 15,516 Jul 08 05:06 PM PARSHALL B LYNNE Director Jul 01 '24 Option Exercise 10.68 5,000 53,400 25,600 Jul 01 05:12 PM PARSHALL B LYNNE Director Jul 01 '24 Sale 54.22 5,000 271,100 20,600 Jul 01 05:12 PM Blum Robert I President & CEO Jul 01 '24 Sale 54.05 11,500 621,575 405,145 Jul 01 05:04 PM Malik Fady Ibraham EVP Research & Development Jun 25 '24 Option Exercise 7.96 5,300 42,188 138,304 Jun 25 08:04 PM Malik Fady Ibraham EVP Research & Development Jun 25 '24 Sale 53.72 7,300 392,143 133,004 Jun 25 08:04 PM PARSHALL B LYNNE Director Jun 17 '24 Option Exercise 10.68 5,000 53,400 25,600 Jun 17 05:17 PM PARSHALL B LYNNE Director Jun 17 '24 Sale 52.55 5,000 262,750 20,600 Jun 17 05:17 PM Blum Robert I President & CEO Jun 17 '24 Sale 52.60 22,500 1,183,391 416,645 Jun 17 05:13 PM Malik Fady Ibraham EVP Research & Development Jun 11 '24 Option Exercise 7.96 5,422 43,159 142,792 Jun 11 04:22 PM Malik Fady Ibraham EVP Research & Development Jun 11 '24 Sale 53.04 7,788 413,106 135,004 Jun 11 04:22 PM Bhanji Muna Director Jun 10 '24 Sale 52.07 2,000 104,140 17,631 Jun 10 04:15 PM Blum Robert I President & CEO Jun 04 '24 Sale 48.85 22,500 1,099,125 439,145 Jun 07 04:03 PM Harrington Robert Arthur Director Jun 03 '24 Sale 48.64 1,580 76,851 15,541 Jun 05 05:23 PM PARSHALL B LYNNE Director Jun 03 '24 Option Exercise 10.68 5,000 53,400 20,600 Jun 04 04:30 PM PARSHALL B LYNNE Director Jun 03 '24 Sale 48.64 5,000 243,200 15,600 Jun 04 04:30 PM Wong Robert VP, Chief Accounting Officer Jun 03 '24 Sale 48.88 13,011 635,978 16,653 Jun 03 04:33 PM Malik Fady Ibraham EVP Research & Development May 07 '24 Option Exercise 6.67 14,186 94,621 152,603 May 07 04:37 PM Malik Fady Ibraham EVP Research & Development May 07 '24 Sale 65.11 15,547 1,012,265 137,056 May 07 04:37 PM HENDERSON JOHN T Director Apr 25 '24 Sale 64.54 10,562 681,671 32,070 Apr 25 06:54 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Option Exercise 6.67 28,605 190,795 171,172 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Sale 74.31 32,605 2,422,918 138,567 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Option Exercise 6.67 28,604 190,789 167,577 Mar 05 04:05 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Sale 67.56 32,604 2,202,606 138,973 Mar 05 04:05 PM HENDERSON JOHN T Director Feb 14 '24 Option Exercise 4.44 5,000 22,200 47,632 Feb 14 04:04 PM HENDERSON JOHN T Director Feb 14 '24 Sale 76.48 5,000 382,400 42,632 Feb 14 04:04 PM Blum Robert I President & CEO Feb 13 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 13 04:01 PM Blum Robert I President & CEO Feb 13 '24 Sale 76.85 12,500 960,625 441,797 Feb 13 04:01 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Option Exercise 6.67 28,605 190,795 175,578 Feb 06 04:43 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Sale 79.30 32,605 2,585,496 142,973 Feb 06 04:43 PM Blum Robert I President & CEO Jan 31 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 02 04:41 PM Blum Robert I President & CEO Jan 31 '24 Sale 79.57 12,500 994,625 441,797 Feb 02 04:41 PM Blum Robert I President & CEO Jan 19 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 22 05:19 PM Blum Robert I President & CEO Jan 19 '24 Sale 81.42 12,500 1,017,750 441,797 Jan 22 05:19 PM HENDERSON JOHN T Director Jan 12 '24 Option Exercise 4.44 5,000 22,200 47,632 Jan 12 05:20 PM HENDERSON JOHN T Director Jan 12 '24 Sale 85.14 5,000 425,700 42,632 Jan 12 05:20 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Option Exercise 7.96 11,678 92,957 162,651 Jan 04 04:36 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Sale 86.98 15,678 1,363,712 146,973 Jan 04 04:36 PM Blum Robert I President & CEO Jan 02 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 02 05:55 PM Blum Robert I President & CEO Jan 02 '24 Sale 85.08 12,500 1,063,500 441,797 Jan 02 05:55 PM WIERENGA WENDALL Director Dec 27 '23 Option Exercise 4.44 10,000 44,400 23,653 Dec 27 04:11 PM WIERENGA WENDALL Director Dec 27 '23 Sale 73.60 10,000 736,000 18,653 Dec 27 04:11 PM Blum Robert I President & CEO Dec 18 '23 Option Exercise 6.67 12,500 83,375 454,297 Dec 19 04:13 PM Blum Robert I President & CEO Dec 18 '23 Sale 36.95 12,500 461,875 441,797 Dec 19 04:13 PM HENDERSON JOHN T Director Dec 18 '23 Option Exercise 6.72 13,020 87,494 44,838 Dec 19 04:12 PM HENDERSON JOHN T Director Dec 18 '23 Sale 36.34 2,458 89,324 42,380 Dec 19 04:12 PM Blum Robert I President & CEO Nov 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Dec 01 04:15 PM Blum Robert I President & CEO Nov 30 '23 Sale 32.99 12,500 412,375 441,417 Dec 01 04:15 PM Blum Robert I President & CEO Nov 15 '23 Option Exercise 6.67 12,500 83,375 453,917 Nov 15 05:22 PM Blum Robert I President & CEO Nov 15 '23 Sale 34.57 12,500 432,125 441,417 Nov 15 05:22 PM Malik Fady Ibraham EVP Research & Development Nov 09 '23 Sale 35.40 2,500 88,500 150,664 Nov 09 04:35 PM Blum Robert I President & CEO Oct 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 30 04:02 PM Blum Robert I President & CEO Oct 30 '23 Sale 32.17 12,500 402,125 441,417 Oct 30 04:02 PM Blum Robert I President & CEO Oct 16 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 16 05:57 PM Blum Robert I President & CEO Oct 16 '23 Sale 33.70 12,500 421,250 441,417 Oct 16 05:57 PM Malik Fady Ibraham EVP Research & Development Oct 12 '23 Sale 35.89 2,500 89,725 153,164 Oct 12 06:39 PM
Index -
P/E -
EPS (ttm) -2.53
Insider Own 8.31%
Shs Outstand 157.71M
Perf Week 1.35%
Market Cap 6.74B
Forward P/E -
EPS next Y -3.39
Insider Trans -0.33%
Shs Float 144.60M
Perf Month -11.25%
Income -365.48M
PEG -
EPS next Q -1.11
Inst Own 90.03%
Short Float 7.03%
Perf Quarter 2.22%
Sales 813.95M
P/S 8.29
EPS this Y -38.56%
Inst Trans -4.20%
Short Ratio 6.29
Perf Half Y 0.02%
Book/sh 1.81
P/B 23.68
EPS next Y 4.33%
ROA -12.91%
Short Interest 10.16M
Perf Year 0.52%
Cash/sh 13.18
P/C 3.24
EPS next 5Y 35.30%
ROE -105.63%
52W Range 35.95 - 54.44
Perf YTD -15.48%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -16.64%
52W High -21.46%
Beta 0.39
Dividend TTM -
Quick Ratio 7.51
Sales past 5Y 13.97%
Gross Margin 95.83%
52W Low 18.94%
ATR (14) 1.70
Dividend Ex-Date -
Current Ratio 7.61
EPS Y/Y TTM -16.73%
Oper. Margin -44.83%
RSI (14) 41.48
Volatility 3.28% 3.61%
Employees 927
Debt/Eq 7.50
Sales Y/Y TTM 29.06%
Profit Margin -44.90%
Recom 1.74
Target Price 61.73
Option/Short Yes / Yes
LT Debt/Eq 7.33
EPS Q/Q 23.83%
Payout -
Rel Volume 1.59
Prev Close 42.74
Sales Surprise 44.15%
EPS Surprise 51.36%
Sales Q/Q 19.55%
Earnings Aug 01 BMO
Avg Volume 1.62M
Price 42.76
SMA20 -6.04%
SMA50 -9.52%
SMA200 -6.33%
Trades
Volume 2,566,873
Change 0.05%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-02-24 Downgrade
BMO Capital Markets
Outperform → Market Perform
$67 → $60
Jul-24-24 Upgrade
Leerink Partners
Market Perform → Outperform
$53 → $62
Jul-16-24 Resumed
Jefferies
Buy
$29 → $75
Jun-14-24 Upgrade
Bernstein
Underperform → Mkt Perform
$44
Apr-10-24 Upgrade
Wolfe Research
Peer Perform → Outperform
$58
Jan-02-24 Upgrade
BofA Securities
Neutral → Buy
$52 → $62
Oct-23-23 Upgrade
BofA Securities
Underperform → Neutral
$33 → $52
Sep-29-23 Initiated
Raymond James
Strong Buy
$63
Jul-31-23 Upgrade
Citigroup
Neutral → Buy
$36 → $60
Jun-07-23 Resumed
Piper Sandler
Overweight
$58
May-04-23 Upgrade
Citigroup
Sell → Neutral
$30 → $36
Mar-21-23 Initiated
Bernstein
Underperform
$31
Dec-21-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$56 → $40
Sep-09-22 Resumed
Morgan Stanley
Overweight
$57
Jul-18-22 Resumed
Oppenheimer
Outperform
$59
Mar-31-22 Resumed
Piper Sandler
Overweight
$54
Mar-01-22 Initiated
Guggenheim
Buy
$64
Mar-01-22 Initiated
Citigroup
Sell
$26
Feb-01-22 Downgrade
BofA Securities
Buy → Underperform
$40 → $30
Dec-14-21 Upgrade
William Blair
Mkt Perform → Outperform
Show Previous Ratings
Sep-12-24 01:01PM
(The Wall Street Journal)
Sep-09-24 09:10PM
04:20PM
Sep-04-24 08:00AM
07:30AM
07:05AM
Loading…
Aug-28-24 07:05AM
Aug-15-24 09:15AM
Aug-13-24 07:00AM
Aug-06-24 11:34PM
Aug-02-24 01:32PM
09:54AM
04:34AM
(Thomson Reuters StreetEvents)
Aug-01-24 10:00AM
08:20AM
07:32AM
(Associated Press Finance)
07:00AM
Loading…
07:00AM
Jul-31-24 09:00AM
Jul-25-24 10:02AM
Jul-23-24 09:53AM
07:03AM
Jul-22-24 04:27PM
(Investor's Business Daily) +5.83%
08:14AM
07:00AM
Jul-19-24 09:56AM
08:24AM
06:32AM
Jul-18-24 07:00AM
Jul-17-24 08:00AM
Jul-08-24 07:05AM
Jun-26-24 12:56PM
06:55AM
Loading…
Jun-25-24 06:55AM
06:30AM
Jun-19-24 12:11PM
Jun-18-24 07:00AM
Jun-17-24 04:09PM
Jun-06-24 11:31AM
May-31-24 12:25PM
07:00AM
May-28-24 07:00AM
May-23-24 07:00AM
May-17-24 10:10AM
May-16-24 12:46PM
10:54AM
08:50AM
08:05AM
07:51AM
07:37AM
07:30AM
07:30AM
07:00AM
May-15-24 07:05AM
May-13-24 07:00AM
May-09-24 06:30AM
May-08-24 03:15PM
10:59AM
10:39AM
05:20AM
(Thomson Reuters StreetEvents)
03:40AM
May-07-24 05:02PM
04:43PM
09:30AM
08:10AM
08:07AM
07:07AM
(Associated Press Finance)
07:00AM
May-06-24 09:15AM
Apr-30-24 10:00AM
Apr-25-24 07:00AM
Apr-23-24 07:05AM
Apr-07-24 09:48AM
Apr-01-24 07:05AM
Mar-28-24 07:05AM
Mar-25-24 09:09AM
08:18AM
Mar-22-24 11:30AM
Mar-21-24 03:00PM
(The Wall Street Journal)
Mar-17-24 08:50AM
Mar-14-24 10:40AM
Mar-13-24 07:17AM
07:07AM
07:00AM
Mar-06-24 07:30AM
Feb-29-24 09:05AM
Feb-28-24 07:05AM
Feb-22-24 12:12PM
10:59AM
10:29AM
02:20AM
(Thomson Reuters StreetEvents)
Feb-21-24 11:31AM
09:30AM
08:05AM
07:06AM
(Associated Press Finance)
07:00AM
Feb-15-24 09:15AM
07:00AM
Feb-14-24 10:00AM
Feb-09-24 10:44AM
Feb-08-24 07:00AM
Feb-07-24 07:05AM
Jan-23-24 01:23PM
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Geary Richard S EVP, Chief Development Officer Aug 29 '24 Sale 49.63 331 16,428 84,823 Sep 03 07:18 PM Geary Richard S EVP, Chief Development Officer Aug 28 '24 Sale 49.16 320 15,731 85,154 Sep 03 07:18 PM Geary Richard S EVP, Chief Development Officer Aug 05 '24 Sale 48.00 2,430 116,640 85,508 Aug 06 05:27 PM Geary Richard S Executive Vice President, Chie Aug 05 '24 Proposed Sale 49.13 3,128 153,678 Aug 05 04:11 PM WENDER JOSEPH H Director Jul 15 '24 Option Exercise 0.00 4,677 0 132,756 Jul 17 05:03 PM PARSHALL B LYNNE Director Jul 15 '24 Option Exercise 0.00 4,677 0 87,265 Jul 17 05:03 PM LOSCALZO JOSEPH Director Jul 15 '24 Option Exercise 0.00 4,677 0 45,759 Jul 17 05:03 PM KLEIN JOSEPH III Director Jul 16 '24 Option Exercise 24.42 12,000 293,040 12,000 Jul 17 05:02 PM KLEIN JOSEPH III Director Jul 16 '24 Sale 50.00 12,000 600,000 0 Jul 17 05:02 PM HERMAN JOAN E Director Jul 15 '24 Option Exercise 0.00 4,677 0 42,007 Jul 17 05:02 PM Diaz Allene M. Director Jul 15 '24 Option Exercise 0.00 4,677 0 17,353 Jul 17 05:02 PM Diaz Allene M. Director Jul 16 '24 Sale 49.49 1,637 81,019 15,716 Jul 17 05:02 PM BERTHELSEN SPENCER R Director Jul 15 '24 Option Exercise 0.00 4,677 0 151,934 Jul 17 05:02 PM BERTHELSEN SPENCER R Director Jun 17 '24 Option Exercise 35.53 16,000 568,480 163,257 Jun 20 05:52 PM BERTHELSEN SPENCER R Director Jun 17 '24 Sale 40.29 16,000 644,640 147,257 Jun 20 05:52 PM WENDER JOSEPH H Director May 09 '24 Option Exercise 35.53 16,000 568,480 128,079 May 13 05:25 PM KLEIN JOSEPH III Director May 03 '24 Sale 42.71 6,000 256,277 0 May 07 04:55 PM Baroldi Joseph EVP, Chief Business Officer Apr 15 '24 Option Exercise 0.00 10,838 0 23,637 Apr 17 05:19 PM Baroldi Joseph EVP, Chief Business Officer Apr 16 '24 Sale 41.60 4,006 166,641 19,631 Apr 17 05:19 PM Birchler Brian EVP, Corp and Development Ops Apr 15 '24 Option Exercise 0.00 1,875 0 47,061 Apr 17 05:16 PM Birchler Brian EVP, Corp and Development Ops Apr 16 '24 Sale 41.66 905 37,698 46,156 Apr 17 05:16 PM Monia Brett P Chief Executive Officer Feb 16 '24 Sale 44.49 387 17,219 173,751 Feb 16 07:47 PM Swayze Eric EVP Research Jan 31 '24 Sale 52.00 10,773 560,196 32,516 Feb 02 07:55 PM Swayze Eric EVP Research Feb 02 '24 Sale 49.56 1,907 94,513 34,324 Feb 02 07:55 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Feb 02 '24 Sale 49.59 2,071 102,701 49,812 Feb 02 07:55 PM O'NEIL PATRICK R. EVP CLO & General Counsel Feb 02 '24 Sale 49.67 1,961 97,410 48,661 Feb 02 07:55 PM Monia Brett P Chief Executive Officer Feb 02 '24 Sale 49.37 23,501 1,160,303 174,138 Feb 02 07:55 PM HOUGEN ELIZABETH L EVP, Finance & CFO Feb 02 '24 Sale 49.54 2,125 105,272 92,905 Feb 02 07:55 PM Geary Richard S EVP, Chief Development Officer Feb 02 '24 Sale 50.04 1,961 98,135 87,334 Feb 02 07:54 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Feb 02 '24 Sale 49.60 2,125 105,404 35,825 Feb 02 07:54 PM BENNETT C FRANK EVP, Chief Scientific Officer Feb 02 '24 Sale 49.52 1,853 91,752 79,079 Feb 02 07:54 PM Monia Brett P Chief Executive Officer Jan 25 '24 Sale 51.75 2,285 118,249 151,851 Jan 29 05:34 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 25 '24 Sale 51.75 6,450 333,788 46,802 Jan 29 05:34 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Jan 16 '24 Option Exercise 0.00 15,062 0 39,374 Jan 18 06:07 PM Cadoret-Manier Onaiza EVP, Chf GL Pdt Str & Oper Ofc Jan 17 '24 Sale 50.42 5,564 280,520 33,810 Jan 18 06:07 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 16 '24 Option Exercise 0.00 20,641 0 60,996 Jan 18 05:59 PM O'NEIL PATRICK R. EVP CLO & General Counsel Jan 17 '24 Sale 50.42 7,744 390,429 53,252 Jan 18 05:59 PM Birchler Brian EVP, Corp and Development Ops Jan 16 '24 Option Exercise 0.00 12,080 0 49,079 Jan 18 05:55 PM Birchler Brian EVP, Corp and Development Ops Jan 17 '24 Sale 50.42 4,497 226,725 44,582 Jan 18 05:55 PM Swayze Eric EVP Research Jan 16 '24 Option Exercise 0.00 21 0 94 Jan 18 05:49 PM Swayze Eric EVP Research Jan 16 '24 Option Exercise 0.00 17,069 0 49,585 Jan 18 05:49 PM Swayze Eric EVP Research Jan 17 '24 Sale 50.42 6,296 317,425 43,289 Jan 18 05:49 PM Swayze Eric EVP Research Jan 17 '24 Sale 50.42 9 454 85 Jan 18 05:49 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 16 '24 Option Exercise 0.00 15,162 0 53,332 Jan 18 05:48 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 17 '24 Sale 50.42 5,482 276,386 47,850 Jan 18 05:48 PM Monia Brett P Chief Executive Officer Jan 16 '24 Option Exercise 0.00 68,084 0 186,195 Jan 18 05:48 PM Monia Brett P Chief Executive Officer Jan 17 '24 Sale 50.42 32,059 1,616,319 154,136 Jan 18 05:48 PM HOUGEN ELIZABETH L EVP, Finance & CFO Jan 16 '24 Option Exercise 0.00 22,487 0 99,573 Jan 18 05:48 PM HOUGEN ELIZABETH L EVP, Finance & CFO Jan 17 '24 Sale 50.42 8,683 437,771 90,890 Jan 18 05:48 PM Geary Richard S EVP, Chief Development Officer Jan 16 '24 Option Exercise 0.00 19,852 0 92,813 Jan 18 05:47 PM Geary Richard S EVP, Chief Development Officer Jan 17 '24 Sale 50.42 7,338 369,960 85,475 Jan 18 05:47 PM BENNETT C FRANK EVP, Chief Scientific Officer Jan 16 '24 Option Exercise 0.00 18,314 0 84,068 Jan 18 05:44 PM BENNETT C FRANK EVP, Chief Scientific Officer Jan 17 '24 Sale 50.42 6,745 340,063 77,323 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 16 '24 Option Exercise 0.00 1,353 0 2,204 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 16 '24 Option Exercise 0.00 3,688 0 14,259 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 17 '24 Sale 50.42 1,460 73,609 12,799 Jan 18 05:44 PM Baroldi Joseph EVP, Chief Business Officer Jan 17 '24 Sale 50.42 564 28,435 1,640 Jan 18 05:44 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 12 '24 Option Exercise 32.60 8,000 260,800 46,170 Jan 17 08:51 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Jan 12 '24 Sale 53.50 8,000 427,999 38,170 Jan 17 08:51 PM Swayze Eric EVP Research Dec 28 '23 Option Exercise 47.34 27,100 1,282,914 59,616 Jan 02 05:54 PM Swayze Eric EVP Research Dec 28 '23 Sale 50.19 27,100 1,360,081 32,516 Jan 02 05:54 PM HOUGEN ELIZABETH L EVP, Finance & CFO Dec 28 '23 Option Exercise 47.34 45,225 2,140,952 120,884 Jan 02 05:54 PM Birchler Brian EVP, Corp and Development Ops Dec 28 '23 Option Exercise 47.34 11,500 544,410 48,028 Jan 02 05:54 PM O'NEIL PATRICK R. EVP CLO & General Counsel Dec 26 '23 Option Exercise 47.34 20,825 985,856 61,180 Dec 28 07:18 PM O'NEIL PATRICK R. EVP CLO & General Counsel Dec 26 '23 Sale 51.46 20,825 1,071,717 40,355 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 27 '23 Option Exercise 47.34 50,000 2,367,000 132,588 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 28 '23 Option Exercise 47.34 42,525 2,013,134 125,113 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 26 '23 Option Exercise 47.34 25,113 1,188,849 107,701 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 27 '23 Sale 50.23 50,000 2,511,515 82,588 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 28 '23 Sale 50.19 42,525 2,134,223 82,588 Dec 28 07:18 PM PARSHALL B LYNNE Director Dec 26 '23 Sale 51.46 25,113 1,292,390 82,588 Dec 28 07:18 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Dec 26 '23 Option Exercise 47.34 25,000 1,183,500 61,052 Dec 28 07:18 PM Schneider Eugene EVP, Chf Clinical Develop Ofcr Dec 26 '23 Sale 51.46 25,000 1,286,575 36,052 Dec 28 07:18 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 21 '23 Option Exercise 47.34 16,113 762,789 81,867 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 72,254 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 21 '23 Sale 49.29 16,113 794,211 65,754 Dec 22 07:11 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 20 '23 Sale 49.64 6,500 322,643 65,754 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 79,461 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 21 '23 Option Exercise 47.34 4,112 194,662 77,073 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 20 '23 Sale 49.64 6,500 322,643 72,961 Dec 22 07:11 PM Geary Richard S EVP, Chief Development Officer Dec 21 '23 Sale 49.29 4,112 202,681 72,961 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 21 '23 Option Exercise 47.34 17,500 828,450 135,611 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 20 '23 Option Exercise 47.34 6,500 307,710 124,611 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 21 '23 Sale 49.29 17,500 862,577 118,111 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 20 '23 Sale 49.64 6,500 322,643 118,111 Dec 22 07:11 PM Monia Brett P Chief Executive Officer Dec 14 '23 Option Exercise 47.34 24,000 1,136,160 132,971 Dec 18 04:56 PM Monia Brett P Chief Executive Officer Dec 14 '23 Sale 49.58 24,000 1,190,019 118,111 Dec 18 04:56 PM Geary Richard S EVP, Chief Development Officer Dec 14 '23 Option Exercise 47.34 10,613 502,419 79,532 Dec 18 04:55 PM Geary Richard S EVP, Chief Development Officer Dec 14 '23 Sale 49.58 10,613 526,236 72,961 Dec 18 04:55 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 14 '23 Option Exercise 47.34 22,612 1,070,452 79,756 Dec 18 04:55 PM BENNETT C FRANK EVP, Chief Scientific Officer Dec 14 '23 Sale 49.58 22,612 1,121,195 65,754 Dec 18 04:55 PM KLEIN JOSEPH III Director Nov 15 '23 Sale 50.00 2,000 100,000 16,346 Nov 17 04:58 PM Swayze Eric EVP Research Oct 16 '23 Option Exercise 0.00 125 0 125 Oct 18 06:40 PM Swayze Eric EVP Research Oct 17 '23 Sale 47.95 52 2,493 73 Oct 18 06:40 PM Monia Brett P Chief Executive Officer Oct 12 '23 Sale 46.00 3,770 173,420 118,111 Oct 16 04:35 PM BENNETT C FRANK EVP, Chief Scientific Officer Sep 28 '23 Sale 46.50 4,460 207,390 65,754 Sep 29 05:20 PM PARSHALL B LYNNE Director Sep 26 '23 Sale 45.13 10,000 451,268 82,588 Sep 28 06:03 PM KLEIN JOSEPH III Director Sep 26 '23 Sale 45.13 2,000 90,254 18,346 Sep 28 06:03 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite